Background {#Sec1}
==========

Autoimmune gastrointestinal dysmotility (AGID) is recognized as a limited form of autoimmune dysautonomia \[[@CR1], [@CR2]\]. Gastrointestinal dysmotility in the patients with autoimmune autonomic ganglionopathy (AAG) is often prominent and may be profound, in some cases \[[@CR3], [@CR4]\]. Autoantibodies (Abs) targeting the ganglionic neuronal nicotinic acetylcholine receptor (gAChR) in autonomic ganglia can potentially cause widespread autonomic dysfunction, leading to AAG \[[@CR5], [@CR6]\]. Several studies have been performed to evaluate the frequency and specificity of serum Abs against neuronal, glial, and muscle antigens in patients clinically diagnosed with AGID, including those with achalasia, gastroparesis, pyloric stenosis, colonic inertia, and intestinal pseudo-obstruction \[[@CR1], [@CR2], [@CR7]--[@CR10]\]. AGID has been clinically associated with cancer and autoimmune rheumatic diseases, and the sera of patients with gut-motility disorders were screened in a few studies for antibodies specific to voltage-gated potassium channels, voltage-gated calcium channels of the P/Q- and N-type, glutamic acid decarboxylase, and neuronal gAChRα3 \[[@CR7]--[@CR10]\]. Recently, we reported that patients with AAG presenting anti-gAChR Abs had severe motility disorders \[[@CR3], [@CR4], [@CR11]\], and demonstrated the existence of the gAChR Abs-related AGID in Japan \[[@CR12]\].

Systemic sclerosis (SSc), a multi-systemic disorder of the connective tissues, is characterized by widespread vascular damage and fibrosis of the skin and visceral organs \[[@CR13], [@CR14]\] Gastrointestinal (GI) manifestations occur frequently in patients with SSc \[[@CR15]--[@CR17]\]. Pseudo-obstruction, malabsorption, gastroesophageal reflux disease (GERD), nausea, vomiting, constipation, and diarrhea are some of the GI complications that can occur in SSc \[[@CR18]--[@CR22]\]. In addition, autonomic dysfunction is also common in SSc, starting early during the disease process and sometimes precedes the development of fibrosis \[[@CR23]--[@CR27]\]. The pathogenesis of GI involvement is thought to include early vascular damage to the vasa nervorum \[[@CR28]\]. This leads to neurological dysfunctions, particularly those involving autonomic pathways.

Humoral immunity dysregulation has been recognized to play an important role in SSc pathogenesis, and numerous Abs can be detected in the sera of patients with SSc \[[@CR29]\]. Three Abs are specific for SSc and serve as specific markers. The anti-centromere antibody (ACA) is the most common marker of limited cutaneous SSc (lcSSc). Anti-scleroderma-70 (anti-Scl-70) is detected mostly in diffuse cutaneous SSc (dcSSc), although 25 to 30% of patients positive for anti-Scl-70 may have lcSSc disease. Anti-RNA polymerase III is also an important biomarker associated with severe dcSSc and a 25% risk of renal crisis \[[@CR29]\]. Earlier studies demonstrated that GI dysmotility in SSc was associated with circulating Abs against the muscarinic AChRs and myenteric neurons \[[@CR19], [@CR29]--[@CR35]\]. Recently, McMahan and colleagues reported patients with SSc and anti-RNPC3 antibodies had moderate-to-severe GI disease and interstitial lung disease \[[@CR36]\].

Recently, we presented the roles of serum biomarkers and endothelial function measurement by Endo-PAT in predicting organ involvement in patients with SSc \[[@CR37]\], and we established a luciferase-reporter immunoprecipitation system (LIPS) assay for detecting the gAChR Abs in a recent study from our laboratory. Using this method, we then aimed to confirm with two step analysis the relationship between the clinical features of SSc, especially GI manifestations, the serum biomarkers, and the anti-gAChR Abs.

Patients and methods {#Sec2}
====================

Ethical approval {#Sec3}
----------------

All subjects provided written, informed consent to participate in this study. Ethical approval was granted by the Ethics Committees of Nagasaki Kawatana Medical Center (approval number 2011-21) and the Nagasaki University Graduate School of Biomedical Sciences (approval number 11032820).

Patients and study design {#Sec4}
-------------------------

This study was cross-sectional. Sixty-three Japanese patients with SSc, who fulfilled the 2013 classification criteria for systemic sclerosis \[[@CR38]\], were consecutively recruited for this study from May 2011 to March 2015. The patients visited Nagasaki University Hospital and Nagasaki Kawatana Medical Center. Thirteen patients were excluded due to insufficient data. Finally, 50 patients with SSc (mean age, 62.2 ± 9.7 years; 6 males and 44 females) were analyzed. Serum and plasma were obtained from all subjects and stored. Patients were grouped according to the classification system proposed by LeRoy et al. \[[@CR39]\]: 34 patients had lcSSc and 16 patients had dcSSc. Six patients had been treated with low-dose corticosteroids (prednisolone, \< 10 mg daily). Four patients had received immunosuppressants including methotrexate, cyclosporin, and tacrolimus. No patients had received vasodilators, such as endothelin receptor antagonists and phosphodiesterase type 5 inhibitors. Ten patients treated with calcium channel blockers against hypertension and nine patients were treated with antiagrregants. All patients underwent a full medical history and physical examination. We reviewed each patient for the presence or absence of comorbid disease, Raynaud's phenomenon, digital ulcers, GERD, renal crisis, interstitial pneumonitis, and pulmonary hypertension \[[@CR34]\]. Laboratory assessments included blood tests, pulmonary function tests, carbon monoxide diffusion capacity testing, chest X-ray and/or high-resolution computed tomography, and transthoracic echocardiography \[[@CR37]\].

Clinical assessment of autonomic function and biomarker measurements {#Sec5}
--------------------------------------------------------------------

Comprehensive clinical and neurological assessments were performed for all patients \[[@CR11], [@CR40]\]. We reviewed clinical survey data and summaries for the patients whether they had any of the following symptoms, which would indicate dysfunction of the autonomic system: orthostatic hypotension (OH) or orthostatic intolerance (OI), arrhythmia, pupillary dysfunction, coughing episodes, dryness of the skin, hypohidrosis or anhidrosis associated with heat intolerance, appetite loss, nausea/vomiting, early satiety, postprandial abdominal pain, and gastroparesis associated with dysfunction of the upper gastrointestinal system, diarrhea or constipation, and paralytic ileus associated with dysfunction of the lower gastrointestinal system, dysuria or urinary retention associated with bladder dysfunction, and sexual dysfunction. Evidence of GI manifestation was determined by physician documentation in the clinical records and/or the presence of at least one symptom of upper and lower digestive systems described above. Gastric and enteric involvement were assessed by performing bedside patient examinations, reviewing the patients' records, and interviewing the patients' families. GERD was ascertained by performing a barium esophagography using the multiphasic cine technique, and esophagitis was assessed by a gastrofiberscope.

Measurements of serum biomarkers, including GDF-15 (R&D Systems, Minneapolis, MN), P*l*GF (R&D Systems), endostatin (R&D Systems), and VEGF (R&D Systems), and the plasma levels of PTX3 (Perseus Proteomics, Tokyo, Japan) were performed as described previously \[[@CR37]\].

In the first step of the present study, patients with SSc were classified into two groups according to the presence or absence of GI manifestations and compared the clinical features and biomarkers described above.

LIPS assay for Abs against gAChR {#Sec6}
--------------------------------

In the second step of the present study, serum gAChR Abs from the patients with SSc were detected by performing the LIPS assay. Subsequently, patients with SSc were classified into the two categories depending of the presence or absence of the gAChR Abs. We compared these two groups and attempted to identify the clinical characteristic of the SSc patients who were seropositive for the gAChR Abs.

We previously established and reported the use of LIPS to diagnose AAG based on IgGs against both the α3 and β4 gAChR subunits in patient serum samples \[[@CR11]\]. We measured the gAChR Abs at the Nagasaki Kawatana Medical Center, as previously described \[[@CR11]\]. To evaluate the diagnostic accuracy of the LIPS assay, we verified the cut-off points for all data collected in the previous study \[[@CR41]\]. Based on the anti-gAChRα3 and β4 Abs data from the healthy control subjects, the cut-off values were calculated as the mean plus three standard deviations (SDs) from the mean \[[@CR42]\]. In this study, antibody levels were expressed as an antibody index (AI) that was calculated as follows: AI = (measured relative luminescence units \[RLU\] value for the serum sample)/(the RLU cut-off value). The normal value established in this study from healthy individuals was an AI of \< 1.0.

Statistical analysis {#Sec7}
--------------------

SigmaPlot® was used for data analysis. Statistical analysis was performed to compare the prevalence of symptoms and associated data between patients with SSc and GI manifestations and those without GI manifestations. The normally distributed data in both groups of patients with SSc were analyzed by a *t* test for the continuous variables (age, age at onset, disease duration, all laboratory data, and the levels of Abs and biomarkers). The Mann--Whitney *U* test was employed in cases where the frequencies of Abs and other patient data were not normally distributed. For the categorical variables, Fisher's exact test was used. For all analyses, *p* \< 0.05 was considered to reflect a statistically significant difference.

Results {#Sec8}
=======

Detection of gAChR Abs in patients with SSc {#Sec9}
-------------------------------------------

Fourteen percent (7 of 50) of the sera samples from patients with SSc were positive for anti-gAChR Abs. More specifically, anti-gAChRα3 antibodies were detected in 7 samples, whereas anti-gAChRβ4 antibodies were detected in 1 sample (2%, 1 of 50). Further, 1 of the serum samples in the group of patients with SSc and GI manifestations was positive for both antibodies.

Clinical features of patients with SSc with or without GI manifestations {#Sec10}
------------------------------------------------------------------------

Only one patient described below demonstrated systemic dysautonomia such as OH/OI, pupillary dysfunction, and GI manifestations. Except for this patient, no patients exhibited systemic dysautonomia. However, GI manifestations were observed in 19 patients with SSc (38%) and were composed of various digestive-system problems, such as GERD (14/19, 74%), constipation (10/19, 53%), appetite loss (9/19, 47%), vomiting (4/21, 21%), early satiety (3/19, 16%), ileus (2/19, 11%), and diarrhea (1/19, 5%). Tables [1](#Tab1){ref-type="table"} and [2](#Tab2){ref-type="table"} summarize the clinical profiles, SSc Abs, laboratory data, serum biomarkers, and gAChR Abs for patients with SSc, either with or without GI manifestations. No significant differences in the clinical profile, SSc Abs, and laboratory data were noted. Various autonomic dysfunction was confirmed in one seropositive case only (patient 1 in Table [2](#Tab2){ref-type="table"}). Table 1Comparison of the clinical features of SSc patients, with and without GI manifestationsSSc with GI manifestations (*n* = 19)SSc without GI manifestations (*n* = 31)*p* valueAge (years)62.1 ± 8.062.3 ± 10.70.934Age at onset (years)54.9 ± 11.555.3 ± 12.90.913Disease duration (years)7.2 ± 7.57.0 ± 8.80.602Sex, female (%)18 (94.7)26 (83.9)0.834Diffuse SSc (%)9 (47.4)8 (25.8)0.394Raynaud's phenomenon (%)19 (100.0)31 (100.0)1.000Digital ulcers (%)6 (31.6)3 (9.7)0.149Renal crisis (%)2 (10.5)0 (0.0)0.158Interstitial pneumonitis (%)8 (42.1)12 (38.7)1.000Pulmonary hypertension (%)2 (10.5)1 (3.2)0.555*Abbreviations*: *GI* gastrointestinal manifestations, *SSc* systemic sclerosis Table 2Summary of the characteristics of 19 patients with SSc and GI manifestationsPatient no. (years, sex)SSc duration, yearsAnti-gAChR AbsLevels of anti-gAChR Abs ^a^, α3/β4Other AbsComplicationsType of SScClinical features (RP, DU, RC, IP, PH)GI manifestation\
(GERD, PI, C, D, and other symptoms ^b^)1 (76, F)3Positive (α3)3.607 (+)/0.212 (−)Scl-70RADiffuseRP, DU, IPC, D2 (57, F)4Positive (α3, β4)2.694 (+)/1.766 (+)ACALimitedRPGERD3 (64, F)12Positive (α3)1.200 (+)/0.516 (−)RNPSSDiffuseRP, PHGERD4 (63, M)0Positive (α3)1.025 (+)/0.838 (−)(Negative)PMDiffuseRP, RC, IPGERD, appetite loss, nausea/vomiting, early satiety, PI, C5 (57, F)3Negative0.420 (−)/0.248 (−)ACASS, PBCLimitedRPGERD, C6 (75, F)2Negative0.431 (−)/0.272 (−)Scl-70SSDiffuseRP, DU, RC, IPAppetite loss7 (64, F)0Negative0.817 (−)/0.482 (−)ACAChronic thyroiditisLimitedRP, IPGERD8 (63, F)26Negative0.368 (−)/0.207 (−)ARSLimitedRP, IPAppetite loss, C9 (61, F)22Negative0.499 (−)/0.582 (−)Scl-70DiffuseRP, DU, IPGERD, appetite loss, C10 (63, F)18Negative0.354 (−)/0.209 (−)Scl-70GPA, RADiffuseRP, IPGERD, appetite loss, nausea/vomiting, C11 (49, F)10Negative0.306 (−)/0.325 (−)ACASSLimitedRPGERD, appetite loss12 (66, F)4Negative0.309 (−)/0.242 (−)ACALimitedRPC13 (44, F)7Negative0.350 (−)/0.255 (−)Scl-70Chronic thyroiditisDiffuseRP, DUGERD14 (68, F)3Negative0.271 (−)/0.277 (−)ACALimitedRPGERD15 (66, F)10Negative0.436 (−)/0.420 (−)Scl-70DiffuseRP, DU, IPGERD, appetite loss16 (63, F)2Negative0.416 (−)/0.253 (−)ACALimitedRPAppetite loss, nausea/vomiting, early satiety, C17 (69, F)6Negative0.540 (−)/0.355 (−)(Negative)LimitedRP, DU, PHGERD18 (51, F)2Negative0.334 (−)/0.336 (−)ACAChronic thyroiditisLimitedRPGERD, C19 (60, F)2Negative0.271 (−)/0.253 (−)(Negative)DiffuseRPGERD, appetite loss, nausea/ vomiting, early satiety, C*Abbreviations*: *Abs* autoantibodies, *ACA* anti-centromere antibodies, *ARS* anti-aminoacyl-tRNA synthetase antibodies, *C* constipation, *D* diarrhea, *DU* digital ulcers, *F* female, *gAChR* ganglionic acetylcholine receptor, *GERD* gastroesophageal reflux disease, *GI* gastrointestinal, *GPA* granulomatosis with polyangiitis, *IP* interstitial pneumonitis, *M* male, *PBC* primary biliary cirrhosis, *PH* pulmonary hypertension, *PI* paralytic ileus, *PM* polymyositis, *RA* rheumatoid arthritis, *RC* renal crisis, *RP* Raynaud's phenomenon, *SS* Sjögren's syndrome, *SSc* systemic sclerosis^a^The normal value of gAChR Abs established from healthy individuals was \< 1.0 AI^b^Other GI manifestations of symptoms included appetite loss, nausea/vomiting, early satiety, and postprandial abdominal pain associated with dysfunction of the upper digestive system

The respective mean levels of anti-gAChRα3 Abs in patients with GI manifestations (+) and GI manifestations (−) were 0.771 AI and 0.452 AI (*p* = 0.001; Table [3](#Tab3){ref-type="table"}), and the respective mean levels of anti-gAChRβ4 Abs in patients with GI manifestations (+) and GI manifestations (−) were 0.424 AI and 0.316 AI (*p* = 0.318; Table [3](#Tab3){ref-type="table"}). The frequencies of gAChR Abs in the groups of SSc patients with GI manifestations (+) or without GI manifestations (−) were 21% (4 of 19), and 10% (3 of 28), respectively (*p* = 0.273; Fig. [1](#Fig1){ref-type="fig"} and Table [3](#Tab3){ref-type="table"}). Table 3Comparison of laboratory findings between SSc patients with and without GI manifestationsSSc with GI manifestations (*n* = 19)SSc without GI manifestations (*n* = 31)*p* valueSeropositive for Anti-gAChRα3 Abs (%)4 (21.1)3 (9.7)0.273Seropositive for Anti-gAChRβ4 Abs (%)1 (5.3)0 (0.0)0.216Anti-gAChRα3 Abs (A.I.)**0.771 ± 0.8890.452 ± 0.4810.001\***Anti-gAChRβ4 Abs (A.I.)0.424 ± 0.3630.316 ± 0.1600.318Other AbsACA (+) (%)8 (42.1)16 (51.6)0.799Anti-Scl70 Abs (+) (%)6 (31.6)6 (19.4)0.521Other Abs (+) (%)2 (10.5)4 (12.9)1.000Negative (%)3 (15.8)6 (16.1)1.000Other laboratory data IgG (mg/dL)1641.9 ± 440.91536.4 ± 371.50.399 KL-6 (U/mL)624.0 ± 692.3560.2 ± 649.50.699 NT-proBNP (pg/mL)211.5 ± 372.7202.7 ± 273.00.757 %FVC101.2 ± 20.699.4 ± 24.50.805 FEV1.0%83.1 ± 9.178.0 ± 17.20.120 %DLCO70.5 ± 21.970.6 ± 17.20.992 DLCO/VA81.0 ± 19.885.5 ± 16.30.427 TR-PG26.7 ± 9.923.3 ± 9.30.259 Estimated PA systolic pressure30.1 ± 6.428.4 ± 9.30.539 EF71.6 ± 6.570.6 ± 6.00.611Serum biomarkers VEGF (pg/mL)**642.4 ± 510.5389.6 ± 423.00.038\*** PIGF (pg/mL)15.7 ± 4.814.7 ± 6.30.270 GDF-15 (pg/mL)1482.4 ± 906.91422.2 ± 947.00.366 PTX3 (ng/mL)3.3 ± 1.72.8 ± 1.00.414 Endostatin (ng/mL)85.3 ± 20.285.4 ± 20.00.990 TGFβ110,580.8 ± 7998.214,707.5 ± 8058.70.060\**p* \< 0.05 was considered statistically significant*Abbreviations*: *Abs* autoantibodies, *ACA* anti-centromere antibodies, *DLCO* diffusing capacity of lung for carbon monoxide, *EF* ejection fraction, *FEV* forced expiratory volume, *FVC* forced vital capacity, *gAChR* ganglionic acetylcholine receptor, *GDF-15* growth differentiation factor-15, *GI* gastrointestinal, *PA* pulmonary artery, *PIGF* placenta growth factor, *PTX3* pentraxin 3, *SSc* systemic sclerosis, *TGFβ1* transforming growth factor β1, *TR-PG* tricuspid regurgitation pressure gradient, *VEGF* vascular endothelial growth factor Fig. 1Schematic representation of study design. Details regarding study design and recruitment for patients in each group. We tested sera from patients with SSc. Using the LIPS assay, we detected autoantibodies against gAChR in 21% (4 of 19) of samples from patients with SSc and GI manifestations, and in 10% (3 of 31) of samples from patients with patients without GI manifestations

Analysis of serum biomarkers revealed that VEGF production was significantly higher in the group of patients with SSc and GI manifestations than in the group with SSc that lacked GI manifestations (*p* = 0.038; Table [3](#Tab3){ref-type="table"}). No correlations were found between the presence of gAChR Abs and clinical profiles, SSc Abs, laboratory data, and serum biomarkers during statistical analysis with all of the samples.

Clinical features of patients with SSc and gAChR Abs {#Sec11}
----------------------------------------------------

The detailed clinical features of patients with SSc, with or without anti-gAChR Abs, are shown in Table [4](#Tab4){ref-type="table"}. In 7 patients with SSc and gAChR Abs, 3 patients (42.9%) had GERD, 2 patients (28.6%) had constipation, 1 patient (14.3%) had paralytic ileus, and 1 patient (14.3%) had diarrhea (Table [4](#Tab4){ref-type="table"}), with some overlap in symptoms occurring between patients. In contrast, the frequencies of each GI manifestation were low in patients with SSc who did not have gAChR Abs, as compared to patients with SSc and gAChR Abs. A tendency was observed where the clinical symptoms of patients with SSc, such as digital ulcers, renal crisis, interstitial pneumonitis, and pulmonary hypertension, were more frequent in patients with SSc that also had gAChR Abs (Table [4](#Tab4){ref-type="table"}). Moreover, while analyzing serum biomarkers in this study, we found that endostatin levels were significantly higher in patients with SSc and gAChR Abs than in SSc patients without gAChR Abs (*p* = 0.046; Table [4](#Tab4){ref-type="table"}). Table 4Clinical profiles of patients with SSc in the presence or absence of gAChR AbsCharacteristicsSSc with gAChR Abs (*n* = 7)SSc without gAChR Abs (*n* = 43)*p* valueAge (years)62.9 ± 14.062.1 ± 9.00.764Age at onset (years)57.1 ± 12.554.8 ± 12.40.646Disease duration (years)5.7 ± 5.67.3 ± 8.70.911Sex, female (%)6 (85.7)38 (88.4)1.000Diffuse SSc (%)4 (57.1)13 (30.2)0.451Raynaud's phenomenon (%)7 (100.0)43 (100.0)1.000Digital ulcers (%)2 (28.6)7 (16.3)0.615Renal crisis (%)1 (14.3)1 (2.3)0.287Interstitial pneumonitis (%)4 (57.1)16 (37.2)0.717Pulmonary hypertension (%)1 (14.3)2 (4.7)0.394GI manifestations GERD (%)3 (42.9)11 (25.6)0.677 Paralytic ileus (%)1 (14.3)1 (2.3)0.287 Constipation (%)2 (28.6)8 (18.6)0.637 Diarrhea (%)1 (14.3)0 (0.0)0.157Other Abs ACA (+) (%)3 (42.9)22 (51.2)1.000 Anti-Scl70 Abs (+) (%)2 (28.6)10 (23.3)1.000 Other Abs (+) (%)1 (14.3)4 (9.3)0.559 Negative (%)1 (14.3)7 (16.3)1.000Other laboratory data IgG (mg/dL)1775.0 ± 614.21548.8 ± 363.60.459 KL-6 (U/mL)666.0 ± 678.3572.6 ± 642.40.534 NT-proBNP (pg/mL)114.1 ± 128.9217.4 ± 418.60.530 %FVC109.8 ± 25.598.8 ± 22.30.311 FEV1.0%78.5 ± 13.679.9 ± 10.00.786 %DLCO61.9 ± 23.871.7 ± 17.50.262 DLCO/VA70.5 ± 15.685.7 ± 17.20.068 TR-PG28.4 ± 17.124.0 ± 7.90.953 Estimated PA systolic pressure26.5 ± 8.529.3 ± 8.40.528 EF71.6 ± 3.470.8 ± 6.70.800Serum biomarkers VEGF (pg/mL)441.6 ± 112.1480.2 ± 476.50.631 PIGF (pg/mL)16.6 ± 6.614.8 ± 8.60.482 GDF-15 (pg/mL)1595.9 ± 1529.01423.1 ± 1086.50.941 PTX3 (ng/mL)2.3 ± 1.23.1 ± 1.50.336 Endostatin (ng/mL)**101.8 ± 21.483.3 ± 18.70.046\*** TGFβ113,038.6 ± 12,382.613,334.3 ± 7692.20.506Immunotherapies Oral PSL (%)1 (14.3)6 (14.0)1.000 Immunosuppressants (%)1 (14.3)3 (7.0)0.532 Steroid pulse therapy (%)0 (0.0)0 (0.0)1.000 IVIg (%)0 (0.0)0 (0.0)1.000 Plasmapheresis (%)0 (0.0)0 (0.0)1.000\**p* \< 0.05 was considered statistically significant*Abbreviations*: *Abs* autoantibodies, *ACA* anti-centromere antibodies, *DLCO* diffusing capacity of lung for carbon monoxide, *EF* ejection fraction, *FEV* forced expiratory volume, *FVC* forced vital capacity, *gAChR* ganglionic acetylcholine receptor, *GDF-15* growth differentiation factor-15, *GERD* gastroesophageal reflux disease, *GI* gastrointestinal, *PA* pulmonary artery, *PIGF* placenta growth factor, *PTX3* pentraxin 3, *SSc* systemic sclerosis, *TGFβ1* transforming growth factor β1, *TR-PG* tricuspid regurgitation pressure gradient, *VEGF* vascular endothelial growth factor

Discussion {#Sec12}
==========

This study is the first to our knowledge to describe the clinical characteristics and biomarkers of the SSc patients who were positive for gAChR Abs. In this study, autonomic function and humoral autoimmunity against the autonomic nervous system were investigated in patients affected by SSc, with a particular focus on GI dysmotility in those patients. Here, we report four major findings: (i) we determined the frequencies of Abs against gAChR in SSc patients with GI manifestations, (ii) the mean levels of anti-gAChRα3 Abs and VEGF were significantly higher in the SSc with GI manifestations group than in the SSc without GI manifestations group, and (iii) endostatin was significantly higher in SSc patients with gAChR Abs than in SSc patients without gAChR Abs.

SSc is a chronic autoimmune disease, and the most common clinical presentations include Raynaud's phenomenon, skin thickening, and tightness caused by widespread vasculopathy and excessive fibrosis \[[@CR13]\]. The GI tract is the commonly involved internal organ in SSc. Vascular changes, collagen accumulation in the submucosa, and smooth muscle atrophy are histological hallmarks of SSc found in the digestive walls of patient biopsies and autopsies \[[@CR16], [@CR20], [@CR21]\]. However, recently, the association between Abs and SSc GI damage has attracted great interest. We found that 21% of the SSc patients with GI manifestations were seropositive for anti-gAChR Abs in this study. The gAChR Abs can potentially impair autonomic ganglionic synaptic transmission. Additionally, because both the sympathetic and parasympathetic ganglia utilize nicotinic cholinergic synapses, Abs that interfere with ganglionic transmission may cause dysautonomia \[[@CR6], [@CR43]\]. Furthermore, the levels of anti-gAChRα3 Abs were significantly higher in SSc patients with GI manifestations. Hence, the gAChR Abs were considered as possible pathogenic humoral factor in the pathomechanism of GI dysmotility in SSc along with Abs against M3R, RNPC3, U1 snRNP, U3 snRNP, signal recognition particle, Ku, and myenteric neuron \[[@CR29], [@CR30], [@CR44]\].

Several previous studies were performed to evaluate autonomic functions in patients with SSc and identify associations with the severity of microvascular damage \[[@CR13], [@CR15]\]. Gigante and colleagues evaluated correlation between autonomic dysfunctions and VEGF production, and they concluded that parasympathetic dysfunction was linked to digital microvascular damage based on data related to heart rate variability and VEGF release \[[@CR45]\]. Neuropilin 1 is a non-tyrosine kinase receptor for VEGF that plays an essential role in GI motility \[[@CR46]\]. In the future, it will be important to verify the role of VEGF and its receptor in autonomic function, especially GI contractility and motility. In this manner, the role of VEGF in the autonomic dysfunctions in SSc could become clear.

In SSc patients with gAChR Abs, clinical profiles involving digital ulcers, renal crisis, interstitial pneumonitis, and pulmonary hypertension were more frequent, although no statistical significances were observed. Previously, some research groups investigated potential biomarkers of SSc, including endostatin, to correlate their levels with serological and clinical parameters \[[@CR47]\]. These previous reports supported the conclusion that higher serum levels of endostatin correlated with angiogenesis and fibrosis disturbances and, thus, may play an important role in SSc. Our present data also showed a high serum concentration of endostatin in SSc patients with gAChR Abs but no clear association of endostatin with the levels of gAChR Abs. The larger sample numbers with prospective observations are necessary to reveal the role of endostatin in the pathomechanism of SSc. The relationship between the role of endostatin and gAChR Abs associated with the autonomic dysfunction has yet to be verified. However, serum endostatin levels could be related to clinical profiles described above for SSc patients with gAChR Abs \[[@CR37]\].

Based on the facts of the present study, the clinical profiles of the group of SSc patients with GI manifestations and the group of SSc patients with the gAChR Abs did not overlap completely (Tables [1](#Tab1){ref-type="table"}, [2](#Tab2){ref-type="table"}, [3](#Tab3){ref-type="table"}, and [4](#Tab4){ref-type="table"}). Only one patient was seronegative in the group of the SSc with gAChR Abs in Table [4](#Tab4){ref-type="table"}. Accordingly, we considered the possibility that the gAChR Abs were produced from the mechanism of SSc autoimmunity. The detailed pathogenesis of such a condition has not been fully elucidated, although GI dysmotility disorders are likely to exist within the broad clinical spectrum of AAG that is etiologically characterized by anti-gAChR Abs. For many years, SSc has been considered a manifestation of an underlying motility disorder. In 1972, Cohen et al. proposed that immune-mediated enteric dysfunction occurred in SSc \[[@CR48]\]. This raises the possibility that motility changes may result from dysfunctions of neurons involved in the enteric nervous system, the vasculature, or elsewhere \[[@CR19]--[@CR21]\]. It is also possible that SSc GI damage occurring in such a case is a variation of AGID, considering that the anti-gAChR Abs might mediate autonomic dysfunction, contributing to the autoimmune mechanisms underlying these GI motility disorders \[[@CR1], [@CR2], [@CR12], [@CR17]\]. Several reports have shown the occurrence of anti-M3R Abs correlating with GI dysmotility in SSc \[[@CR32]--[@CR34]\], as well as the efficacy of intravenous immunoglobulin (IVIg) due to anti-idiotypic neutralization \[[@CR34]\]. As with the gAChR, the M3R exists in human autonomic nervous system. Although GI dysmotility in SSc with the anti-gAChR Abs could be considered a form of AGID in a broad sense, we recommend future experimentation be performed to test the hypothesis that immune cell--endothelial nerve interactions (even with anti-gAChR Abs) are related autonomic dysfunction, including GI manifestations, in SSc. Our results suggest rheumatologists and neurologists should be aware of the necessity of measuring the levels of anti-gAChR Abs in SSc cases with autonomic dysfunction including GI manifestations.

Conclusions {#Sec13}
===========

In conclusion, we determined the clinical characteristics of SSc patients with seropositivity for the anti-gAChR Abs, and considered the relationship among gAChR Abs, several biomarkers, and GI manifestations in SSc. However, the present study has important limitations that should be noted, namely, the observational study design and the small sample size. A prospective, clinical interventional, multicenter cohort study will be necessary to confirm the relationships between the levels of anti-gAChR Abs, serum biomarkers (including VEGF and endostatin), and autonomic function (including the severity of GI dysmotility in SSc) versus the outcomes of immunotherapies. Moreover, it is necessary to clarify whether a direct link exists between the presence of gAChR Abs and the specific interference in synaptic transmission in autonomic ganglia including GI tract.

AAG

:   Autoimmune autonomic ganglionopathy

Abs

:   Antibodies

ACA

:   Anti-centromere antibody

AGID

:   Autoimmune gastrointestinal dysmotility

AI

:   Antibody index

CVRR

:   Coefficient of variation in R-R intervals

dcSSc

:   Diffuse cutaneous SSc

gAChR

:   Ganglionic acetylcholine receptor

GERD

:   Gastroesophageal reflux disease

GI

:   Gastrointestinal

IVMP

:   Intravenous methylprednisolone

lcSSc

:   Limited cutaneous SSc

LIPS

:   Luciferase immunoprecipitation system

NE

:   Norepinephrine

OH

:   Orthostatic hypotension

OI

:   Orthostatic intolerance

RLU

:   Relative luminescence units

SD

:   Standard deviation

SSc

:   Systemic sclerosis
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